Myriad Genetics, Inc.
HealthcareNASDAQ:MYGN · NASDAQ Global Select
-$0.30 today
Vol 1.19M · Avg 1.84M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-99.4%
avg -16.1%
ROIC
-10.8%
avg -6.3%
ROA
-51.8%
avg -9.1%
Analysis
ROIC is currently the strongest return metric at -10.8% versus its period average of -6.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Samraat S. Raha | President, Chief Executive Officer & Director | $1.70M | — | 53 | $1.07M | 1.13% |
Paul J. Diaz | Consultant | $1.52M | — | 64 | $157,142.00 | 0.17% |
Brian Donnelly | Chief Commercial Officer | $1.20M | — | 43 | $573,363.00 | 0.61% |
Mark S. Verratti | Chief Operating Officer | $1.09M | — | 58 | $1.07M | 1.13% |
Benjamin R. Wheeler | Chief Financial Officer & Principal Accounting Officer | $748,668.00 | — | 42 | $298,509.00 | 0.32% |
Dale Muzzey | Chief Scientific Officer | $741,858.00 | — | 46 | $326,310.00 | 0.35% |
Raj Jampa | Chief Technology Officer | $580,360.00 | — | — | $251,889.00 | 0.27% |
Patrick Burke | Executive Vice President of Innovation & Strategic Partnerships | — | — | — | — | — |
Matthew Scalo | Senior Vice President of Investor Relations | — | — | — | — | — |
Jennifer L. Fox | Chief Legal Officer | — | — | 53 | $310,362.00 | 0.33% |
Shereen Solaiman | Chief People Officer | — | — | 53 | $267,801.00 | 0.28% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$722,203.92
Sells
1
$66,843.00
Net Sentiment
+$655,360.92
Net buying
Most Active
Phanstiel S. Louise
3 transactions
Analysis
Insiders reported 5 buys worth $722,203.92 and 1 sells worth $66,843.00 over the last 12 months. That adds up to net buying of $655,360.92. Phanstiel S. Louise was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -1.1% | -6.3% (15yr)1 analysts |
| Revenue | N/A | N/A | +7.1% | +2.5% (15yr)3 analysts |
| Net Income | N/A | N/A | -5.2% | -4.8% (15yr)3 analysts |
| EBIT | N/A | N/A | -9.9% | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +7.1% over three years. Forward estimates point to Revenue at +2.5% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.45B
AMN Healthcare Services, Inc.
NYSE:AMN
$1.19B
CareDx, Inc
NASDAQ:CDNA
$1.19B
Personalis, Inc.
NASDAQ:PSNL
$851.63M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$722.58M
Castle Biosciences, Inc.
NASDAQ:CSTL
$627.83M
Evolent Health, Inc.
NYSE:EVH
$539.91M
Fulgent Genetics, Inc.
NASDAQ:FLGT
$530.52M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$515.41M
DarioHealth Corp.
NASDAQ:DRIO
$51.63M
Who manages MYGN?
Myriad Genetics, Inc. (MYGN) lists 11 active executives. The top listed executive is Benjamin R. Wheeler, Chief Financial Officer & Principal Accounting Officer.
Are MYGN insiders buying or selling?
Recent insider activity shows net selling of $16.80M.
Explore More
Continue the stock analysis
Jump to another research area for this company.